Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a … Read more
Cullinan Oncology LLC - Asset Resilience Ratio
Cullinan Oncology LLC (CGEM) has an Asset Resilience Ratio of 47.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Cullinan Oncology LLC's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cullinan Oncology LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $229.26 Million | 47.36% |
| Total Liquid Assets | $229.26 Million | 47.36% |
Asset Resilience Insights
- Very High Liquidity: Cullinan Oncology LLC maintains exceptional liquid asset reserves at 47.36% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cullinan Oncology LLC Industry Peers by Asset Resilience Ratio
Compare Cullinan Oncology LLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Cullinan Oncology LLC (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Cullinan Oncology LLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 50.81% | $315.97 Million | $621.82 Million | -25.32pp |
| 2023-12-31 | 76.14% | $368.63 Million | $484.18 Million | +20.69pp |
| 2022-12-31 | 55.45% | $311.14 Million | $561.12 Million | +2.68pp |
| 2021-12-31 | 52.77% | $230.69 Million | $437.19 Million | +33.20pp |
| 2020-12-31 | 19.57% | $42.01 Million | $214.71 Million | -15.65pp |
| 2019-12-31 | 35.22% | $35.38 Million | $100.46 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $34.64 Million | -- |